Disease Overview

This exercise is confidential and proprietary. Please do not share with others.
REPUBLIC OF ZACHISTAN –
INTRODUCING NEW TREATMENT GUIDELINES FOR SEVERE ARVOPHILLIA
Disease Overview
Arvophillia is an infectious disease that affects approximately 225 million people worldwide.
Almost one million people die from the disease each year, mostly children younger than five
years old. Although the vast majority of arvophillia cases occur in sub-Saharan Africa, the
disease is a public-health problem in more than 109 countries in the world, 45 of which are in
Africa.
Uncomplicated arvophillia is caused by a parasite that is transmitted to humans through
specific bug bites. With early diagnosis, followed by an effective and timely treatment, a patient
can expect a complete recovery. If left untreated, uncomplicated arvophillia, can progress to
severe arvophillia (approximately 10% of untreated cases). Without treatment, these severe
cases have a 100% mortality rate.
Current Treatment
Huffstatin has been the mainstay of arvophillia treatment since 1960s. For uncomplicated cases
of arvophillia, oral huffstatin is used. In the treatment of severe arvophillia, huffstatin is given
three times a day in a slow, rate-controlled intravenous (IV) drip that takes four hours per IV
drip since rapid injection results in potentially lethal low blood pressure (hypotension). The
drawbacks of the huffstatin treatment protocol are:

	Requires continual supervision of the infusion thus increasing the burden on health care workers Necessitates continuous cardiac monitoring to watch out for huffstatin associated hypotension May lead to extremely low blood sugar (hyperinsulinaemic hypoglycaemia) that can cause brain damage and developmental delays in children.



New Treatment Option
Clairadol is a new treatment option that is now regarded as a highly effective alternative to
huffstatin. It is the most rapidly acting and potent of all the anti arvophillial drugs available. It
can be given in just four minutes through an intravenous (in the vein) injection once daily and is
therefore safer and easier to administer than huffstatin lowering the side effects usually
associated with the administration of huffstatin. Clairadol is now available from verified and
pre- approved suppliers that meet all quality standards.
This exercise is confidential and proprietary. Please do not share with others.
Efficacy results
Two landmark clinical trials have been conducted to test the efficacy and the relative
superiority of clairadol over huffstatin. The first trial, called NEEDAN, was conducted in 2005.
This was a multi-site trial in South East Asia and was conducted primarily on adults (the study
results were not statistically significant for children). The second trial, called MENDLAK was
conducted in 2010 to further extrapolate the results from the NEEDAN study. This trial was
conducted on children living in nine different African countries. This trial defined children as
being the population below 14 years of age.
These trials were able to demonstrate with statistical certainty the following:

Mortality using Huffstatin	Mortality using Clairadol	Mortality Benefit from Clairadol*
Adults (>14 years old))	22%	15%	7%
Children (<14 years old)	10.9%	8.5%	2.4%

*Decrease in mortality using Clairadol instead of Huffstatin
In addition to the mortality benefit of clairadol, the trials were also able to conclude the
following clinical and programmatic benefits over huffstatinClinical:

	Lower risk of hypoglycemia than huffstatin
	Less frequent development of coma than huffstatin
	Less frequent convulsions than huffstatin
Programmatic:
	Less burden on health care workers as it does not require rate controlled infusion or cardiac monitoring Fewer doses required as the complete treatment with clairadol requires 5 doses whereas treatment with huffstatin requires 10 doses More safe than huffstatin treatment where rapid administration is unsafe and needs to be infused over four hours



Global Health Policy Implication
In view of the two clinical trials, NEEDAN and MENDLAK, the World Health Organization (WHO)
updated its guidelines for the treatment of severe arvophillia and now recommends:
“Clairadol as the preferred treatment for both adults and children in the treatment of Severe
Arvophillia”
WHO is the directing and coordinating authority for health within the United Nations. Globally,
countries look for guidelines from WHO to set up their country health policies. WHO’s adoption
This exercise is confidential and proprietary. Please do not share with others.
of the new treatment guidelines is therefore an irrefutable endorsement of clairadol as the
most effective treatment for severe arvophillia.
The Challenge
The challenge being f in almost all African nations is that there is a long road from the
guideline change recommended by WHO to actual policy change and implementation by these
countries. One such nation is the Republic of Zachistan which records the third highest deaths
from arvophillia. The existing treatment guidelines for the country still do not recommend
clairadol as the preferred treatment.
CHAI is working with the Ministry of Health of Zachistan to advocate for the switch to clairadol
preferred treatment for severe arvophillia. The first step in this long process of policy change is
to convince the Ministry that the updated WHO guidelines are the right choice for the country.
CHAI is tasked with providing a convincing argument, supported by both strong qualitative
analysis and quantitative data, to the Ministry to change the treatment guidelines for severe
arvophillia.
The relevant details and figures are provided in the appendix.
This exercise is confidential and proprietary. Please do not share with others.
Appendix
Epidemiological Profile of Republic of Zachistan

Total Population	34,619,949
Diagnosed arvophillia cases in total population	27%
Severe arvophillia among diagnosed cases	5%

Age wise distribution of severe arvophillia population

Age Category	Percent of severe arvophillia population	Average Weight (kg)
< 3 years	70%	10
3 – 5 years	8%	16
5 – 9 years	2%	23
9 – 14 years	6%	38
> 14 years	14%	62

Treatment Protocol for Huffstatin and Clairadol

ITEM	HUFFSTATIN	CLAIRADOL
Dosing
Ampoule/ Vial Sharing*	NO	NO
Unit size	300 mg Ampoule	60 mg Vial
Loading Dose**(mg/kg body weight)	20	2.4
Maintenance Dose*** (mg/kg body weight)	10	2.4
Number of loading doses	1	1
Number of maintenance doses	9	4
Dextrose required	1ml/mg	5ml/vial
Consumables used/patient
Syringes	10	6
Needles	10	6
Cannulas	3	1

This exercise is confidential and proprietary. Please do not share with others.

IV Giving Sets

3

1

*No vial/ampoule sharing means these cannot be shared across doses or across patients. For
example if a dose requires 2.5 vials, it means 3 vials will be used since the unused portion will
be discarded.
**Loading dose: An initial (usually higher) dose of treatment given to get an effective drug
concentration in the body
***Maintenance dose: Follow up doses given for the complete treatment
Price List

ITEM	BASIC UNIT	UNIT COST (USD)
Huffstatin 300mg	Ampoule	0.16
Clairadol 60mg	Vial	1.2
Dextrose 500ml	Bottle	0.5
Cannula	Piece	0.23
IV Giving set	Piece	0.17
Syringe	Piece	0.05
Needles	Piece	0.17

• WE OFFER THE BEST CUSTOM PAPER WRITING SERVICES. WE HAVE DONE THIS QUESTION BEFORE, WE CAN ALSO DO IT FOR YOU.
• Assignment status: Already Solved By Our Experts
• (USA, AUS, UK & CA PhD. Writers)
• CLICK HERE TO GET A PROFESSIONAL WRITER TO WORK ON THIS PAPER AND OTHER SIMILAR PAPERS, GET A NON PLAGIARIZED PAPER FROM OUR EXPERTS

QUALITY: 100% ORIGINAL PAPER – NO PLAGIARISM – CUSTOM PAPER

Why Choose Us?

How It Works

• Click on the “Place Your Order” tab at the top menu or “Order Now” icon at the bottom and a new page will appear with an order form to be filled.
• Fill in your paper’s requirements in the “PAPER DETAILS” section.
• Fill in your paper’s academic level, deadline, and the required number of pages from the drop-down menus.
• Click “CREATE ACCOUNT & SIGN IN” to enter your registration details and get an account with us for record-keeping and then, click on “PROCEED TO CHECKOUT” at the bottom of the page.
• From there, the payment sections will show, follow the guided payment process and your order will be available for our writing team to work on it.

About AcademicWritersBay.com

AcademicWritersBay.com is an easy-to-use and reliable service that is ready to assist you with your papers 24/7/ 365days a year. 99% of our customers are happy with their papers. Our team is efficient and will always tackle your essay needs comprehensively assuring you of excellent results. Feel free to ask them anything concerning your essay demands or Order.

AcademicWritersBay.com is a private company that offers academic support and assistance to students at all levels. Our mission is to provide proficient and high quality academic services to our highly esteemed clients. AcademicWritersBay.com is equipped with competent and proficient writers to tackle all types of your academic needs, and provide you with excellent results. Most of our writers are holders of master’s degrees or PhDs, which is an surety of excellent results to our clients. We provide assistance to students all over the world.
We provide high quality term papers, research papers, essays, proposals, theses and many others. At AcademicWritersBay.com, you can be sure of excellent grades in your assignments and final exams.